InvestorsHub Logo
Followers 51
Posts 3078
Boards Moderated 0
Alias Born 05/11/2016

Re: None

Friday, 10/13/2017 8:26:54 AM

Friday, October 13, 2017 8:26:54 AM

Post# of 33238
"Heart failure and vascular diseases are potential clinical targets for our non-invasive electroceuticals. These results demonstrate the incredible potential of electroceutical-based therapies," said Alan Collier, CEO of Endonovo Therapeutics. "We plan to submit our preclinical post-MI remodeling results during 2018 for presentation at a relevant scientific meeting as we continue to advance our class-leading non-invasive electroceuticals toward the clinic."


$ENDV



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENDV News